Usual Adult Dose for Basal Cell Carcinoma

150 mg orally once a day until disease progression or unacceptable toxicity

Comments:

• Withhold therapy for up to 8 weeks for intolerable adverse reactions until improvement or resolution.
• Treatment durations shorter than 8 weeks prior to interruptions have not been studied.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

US BOXED WARNINGS:
EMBRYOFETAL TOXICITY:

• This drug can cause embryofetal death or severe birth defects when administered to a pregnant woman.
• This drug is embryotoxic, fetotoxic, and teratogenic in animals.
• Teratogenic effects include severe midline defects, missing digits, and other irreversible malformations.
• Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating therapy.
• Advise pregnant women of the potential risks to a fetus.
• Advise females of reproductive potential to use effective contraception during and after therapy.
• Advise males of the potential risk of drug exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential.

• None

Dialysis

Data not available

Other Comments

Administration advice:

• This drug may be taken with or without food.
• Swallow capsules whole; do not open or crush.
• If a dose of is missed, do not make it up; resume with the next scheduled dose.
• Verify pregnancy status of females of reproductive potential within 7 days prior to initiating this drug.

• Store at room temperature 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).
• Keep the bottle tightly closed to protect from moisture.

• Pregnancy

• Advise patients that exposure during pregnancy can cause embryofetal death or severe birth defects.

Frequently asked questions

• What are the most common skin conditions? (with photos)